<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="100000"><DrugName>IDE-196</DrugName><DrugSynonyms><Name><Value>NVP-LXS-196</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>LXS-196</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IDE-196</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>protein kinase C inhibitor (oral, uveal melanoma/solid tumor), IDEAYA Biosciences</Value></Name><Name><Value>protein kinase C inhibitor (oral, uveal melanoma), Novartis</Value></Name></DrugSynonyms><CompanyOriginator id="24818">Novartis Pharmaceuticals Corp</CompanyOriginator><CompaniesPrimary><Company id="1123262">IDEAYA Biosciences Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="24818">Novartis Pharmaceuticals Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1123262" type="Company"><TargetEntity id="5046317163" type="organizationId">IDEAYA Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="24818" type="Company"><TargetEntity id="5000031450" type="organizationId">Novartis Pharmaceuticals Corp</TargetEntity></SourceEntity><SourceEntity id="205" type="ciIndication"><TargetEntity id="C43" type="ICD10"></TargetEntity><TargetEntity id="10025650" type="MEDDRA"></TargetEntity><TargetEntity id="D008545" type="MeSH"></TargetEntity><TargetEntity id="-361092282" type="omicsDisease"></TargetEntity><TargetEntity id="705" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3788" type="ciIndication"><TargetEntity id="D014604" type="MeSH"></TargetEntity><TargetEntity id="39044" type="ORPHANET"></TargetEntity><TargetEntity id="-1746823282" type="omicsDisease"></TargetEntity><TargetEntity id="2045" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"></TargetEntity><TargetEntity id="D015179" type="MeSH"></TargetEntity><TargetEntity id="-1280257855" type="omicsDisease"></TargetEntity><TargetEntity id="594" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="334" type="Action"><TargetEntity id="482" type="Mechanism">Protein Kinase C (PKC) Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><IndicationsPrimary><Indication id="205">Melanoma</Indication><Indication id="3788">Uveal melanoma</Indication><Indication id="725">Solid tumor</Indication><Indication id="989">Colorectal tumor</Indication></IndicationsPrimary><ActionsPrimary><Action id="334">Protein kinase C inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2019-07-02T04:31:50.000Z</LastModificationDate><ChangeDateLast>2019-07-03T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-28T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1123262" linkType="Company"&gt;IDEAYA Biosciences&lt;/ulink&gt; under license from&lt;ulink linkID="24818" linkType="Company"&gt;  Novartis Pharmaceuticals&lt;/ulink&gt; is developing  IDE-196 (previously LXS-196; NVP-LXS-196), an oral protein kinase C inhibitor, for the potential treatment of metastatic uveal melanoma. IDEAYA is also investigating the drug, for the potential treatment of  solid tumors   including, cutaneous melanoma, and colorectal cancer [&lt;ulink linkID="1715287" linkType="Reference"&gt;1715287&lt;/ulink&gt;], [&lt;ulink linkID="2086074" linkType="Reference"&gt;2086074&lt;/ulink&gt;]. In February 2016, a phase I trial  in  patients with metastatic uveal melanoma was initiated [&lt;ulink linkID="1715287" linkType="Reference"&gt;1715287&lt;/ulink&gt;]; in May 2018, data were presented [&lt;ulink linkID="2038856" linkType="Reference"&gt;2038856&lt;/ulink&gt;]. In June  2019, 	an agnostic basket study was initiated in  solid tumor patients with mutations of GNAQ and GNA11 [&lt;ulink linkID="2086074" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="2151643" linkType="Reference"&gt;2151643&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In October 2018, 	an agnostic basket study was planned in  solid tumor patients with mutations of GNAQ and GNA11 [&lt;ulink linkID="2086074" linkType="Reference"&gt;2086074&lt;/ulink&gt;]. In May 2019, the US FDA approved an IND application to initiate a phase I/II tissue-type agnostic basket trial in the second or third quarter of that year,  to evaluate IDE-196 in patients with solid tumors harboring GNAQ/11 mutations or PKC fusions, including, but not limited to, metastatic uveal melanoma (UM), cutaneous melanoma, and colorectal cancer [&lt;ulink linkID="2149246" linkType="Reference"&gt;2149246&lt;/ulink&gt;]. At that time, the interventional, non-randomized, sequential assignment, open label study (&lt;ulink linkID="380335" linkType="Protocol"&gt;NCT03947385&lt;/ulink&gt;; IDE196-001)  was to begin in solid tumor patients (expected n = 166) in July 2019 and expected to complete in April 2023 [&lt;ulink linkID="2151643" linkType="Reference"&gt;2151643&lt;/ulink&gt;]. In May 2019, the US FDA approved an IND filling for  phase I/II trial, which was to begin in the second or third quarter of that year [&lt;ulink linkID="2149246" linkType="Reference"&gt;2149246&lt;/ulink&gt;]. In June 2019, the trial was initiated in the US for the treatment of metastatic uveal melanoma, cutaneous melanoma, colorectal cancer and solid tumors [&lt;ulink linkID="2151643" linkType="Reference"&gt;2151643&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2016, an open-label, single group-assigned, non-randomized, multicenter phase I trial (&lt;ulink linkID="245578" linkType="Protocol"&gt;NCT02601378&lt;/ulink&gt;; CLXS196X2101) was initiated in  the US, Australia, France, the Netherlands and Spain, in patients (expected n = 112) with metastatic uveal melanoma, to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS-196 as a single agent (68 patients) and in combination with &lt;ulink linkID="91398" linkType="Drug"&gt;HDM-201&lt;/ulink&gt; (44 patients). At that time, the trial was expected to complete in October 2019 [&lt;ulink linkID="1715287" linkType="Reference"&gt;1715287&lt;/ulink&gt;]. In May 2018, data were presented at the 8th RSC/SCI Kinase Inhibitor Design Symposium in Cambridge, UK. LXS-196 had been dosed at up to 800 mg qd or 400 mg bid, and demonstrated  an 8 h half-life and a Tmax of approximately 1 h. Out of 55 treated patients, stable disease was achieved by 38, with 5 exhibiting partial responses. Typical kinase inhibitor side effects, such as nausea and diarrhea were observed [&lt;ulink linkID="2038856" linkType="Reference"&gt;2038856&lt;/ulink&gt;]. In March 2019, similar data were presented at the 2019 ASCPT Annual Meeting in Washington DC.Hypotension was the most common adverse event and DLT [&lt;ulink linkID="2129081" linkType="Reference"&gt;2129081&lt;/ulink&gt;], &lt;ulink linkID="2130150" linkType="Reference"&gt;2130150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2019, clinical data presented from an open label, phase I dose escalation study which evaluated safety and efficacy of LXS-196 in patients with metastatic uveal melanoma were presented at the 2019 AACR Annual Meeting in Atlanta, GA. Patients received LXS196 orally in either qd or bid dosing schedules. MTD was 500 mg qd and 400 mg bid. In qd (n = 38) and bid  (n = 30) schedules, partial response was observed in 2 and 4 patients; stable disease was observed in 27 and 18 patients; progressive disease was observed in 24 and 20% patients, respectively; ORR was 5 and 13% and DCR was 76 and 73%, respectively. In the bid schedule, the median PFS was 4.14 months; median duration of stable disease was 5.37 months. Recommended Dose for Expansion was declared at 300 mg bid and a further 12 patients were enrolled for expansion dose. Majority of adverse events were mild to moderate, manageable and reversible without dose reduction [&lt;ulink linkID="2133766" linkType="Reference"&gt;2133766&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2017, in vivo data were presented at the 253rd ACS National Meeting and Exhibition in San Francisco, CA. Regression was observed at multiple doses of NVP-LXS-196 (15, 30, 75, 150, 120 mg/kg bid), and maximum efficacy was exhibited at dosage 150 mg/kg (bid). NVP-LXS-196 demonstrated dose-dependent pharmacokinetics across GNAQ xenograft models of multiple species like mouse, rat, dog, monkey and human [&lt;ulink linkID="1914650" linkType="Reference"&gt;1914650&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2018, data were presented at the 8th RSC/SCI Kinase Inhibitor Design Symposium in Cambridge, UK. LXS-196 was a potent inhibitor of PKCalpha and PKCtheta with IC50 values of 0.2 and 2 nM, respectively. In A921 cells it had an IC50 value of 140 nM and was active at 30 mg/kg in a xenograft model expressing mutant GNAQ; 4-fold more potent than AEB-071 [&lt;ulink linkID="2038856" linkType="Reference"&gt;2038856&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1123262">IDEAYA Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-06-25T00:00:00.000Z</StatusDate><Source id="2151643" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123262">IDEAYA Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-06-25T00:00:00.000Z</StatusDate><Source id="2151643" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123262">IDEAYA Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-06-25T00:00:00.000Z</StatusDate><Source id="2151643" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123262">IDEAYA Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-06-25T00:00:00.000Z</StatusDate><Source id="2151643" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123262">IDEAYA Biosciences Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-23T00:00:00.000Z</StatusDate><Source id="2086074" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123262">IDEAYA Biosciences Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-23T00:00:00.000Z</StatusDate><Source id="2086074" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24818">Novartis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-23T00:00:00.000Z</StatusDate><Source id="2086074" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24818">Novartis Pharmaceuticals Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-23T00:00:00.000Z</StatusDate><Source id="2086074" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24818">Novartis Pharmaceuticals Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-23T00:00:00.000Z</StatusDate><Source id="2086074" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24818">Novartis Pharmaceuticals Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1715287" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24818">Novartis Pharmaceuticals Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1715287" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24818">Novartis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-06T00:00:00.000Z</StatusDate><Source id="1715287" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24818">Novartis Pharmaceuticals Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-02-01T00:00:00.000Z</StatusDate><Source id="1715287" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24818">Novartis Pharmaceuticals Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-02-01T00:00:00.000Z</StatusDate><Source id="1715287" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24818">Novartis Pharmaceuticals Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-02-01T00:00:00.000Z</StatusDate><Source id="1715287" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123262">IDEAYA Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3788">Uveal melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-23T00:00:00.000Z</StatusDate><Source id="2086074" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123262">IDEAYA Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-23T00:00:00.000Z</StatusDate><Source id="2086074" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123262">IDEAYA Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-23T00:00:00.000Z</StatusDate><Source id="2086074" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123262">IDEAYA Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-23T00:00:00.000Z</StatusDate><Source id="2086074" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01618"><Name>Protein kinase C</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2151643" linkType="reference" linkID="2151643"&gt;2151643&lt;/ulink&gt;]
							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1123262">IDEAYA Biosciences Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC1(CCN(CC1)c2cccnc2NC(=O)c3c(ncc(n3)c4c(cccn4)C(F)(F)F)N)N</Smiles></StructureSmiles><Deals><Deal id="250746" title="Ideaya to develop and commercialize Novartis' LXS-196 against MUM worldwide "></Deal></Deals><PatentFamilies><PatentFamily id="4434142" number="WO-2019053595" title="Protein kinase c inhibitors for treatment of uveal melanoma"></PatentFamily><PatentFamily id="4461549" number="WO-2019069195" title="Method for preparing a pharmaceutical product"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>